|

Furmonertinib Clinical Trials

14 actively recruiting trials

Also known as: AST2818, Furmonertinib Mesylate, Ivesa, bevacizumab, pemetrexed

Pipeline

Phase 2: 9Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Sun Yat-sen University2
  • Peking Union Medical College Hospital2
  • Tianjin Medical University Cancer Institute and Hospital1
  • Tang-Du Hospital1
  • Shanghai Pulmonary Hospital, Shanghai, China1

Indications

  • Cancer14
  • Lung Cancer13
  • Non Small Cell Lung Cancer7
  • NSCLC2
  • EGFR Gene Mutation2

Other14 trials

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Phase 2
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Phase 1/2
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Phase 2
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
N/A
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Phase 3
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Phase 2
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Phase 2
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Phase 2
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Phase 2
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Phase 1/2
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Phase 2
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.